Cellectricon and Neurexpert Collaborate To Offer Enhanced offering In CNS Drug Discovery
News Jun 08, 2016
Cellectricon AB, a leading provider of advanced cell-based Discovery Services, announced a commercial collaboration with UK-based research company Neurexpert Ltd. Under the agreement,Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.
“As a provider of specialist neurophysiology expertise and with over 80 years combined experience in developing electrophysiological assays to test the action of novel compounds on neuronal synaptic function, we are very excited about this collaboration with Cellectricon,” said Neurexpert co-founder Professor Tom Salt. “With our extensive CNS expertise, we believe that we provide important domain knowledge that adds further value to Cellectricon’s proprietary Cellaxess® Elektra Discovery Services screening platform and expert scientific staff”.
“Through our collaboration with Neurexpert, we have further enhanced our Discovery Services offering for CNS research”, said Cellectricon’s VP Commercial & Technology, Mattias Karlsson. “The additional range of complementary cell-based assays that bridge the gap between in vitro and in vivo screens provides assurance that potency and selectivity data translate into physiologically-relevant activity, thereby confirming mechanism of action. Being able to access the information-rich assays and specialist expertise of the Neurexpert team gives essential functional and mechanistic validation to complement and expand our Discovery Services techniques – a real value-add for our clients”.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
High-throughput Screening: Microscale Thermophoresis to Characterize HitsNews
A new perspective article details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018